醣基生醫股份有限公司 Approved
最後更新時間 2025/07/11 , 06:35 AM
最後更新時間 2025/07/11 , 06:35 AM
負責人
Chen,Zhao-Long
統一編號
54170142
成立日期
2013/03/08
資本額
NT$2,500,000,000
實收資本額
NT$2,140,105,000
股票代號
6586
電話
02-26558059
地址
7F, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City, 115, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Chen,Zhao-Long Chairman 0.00%
Cai,Ming-Xing Director 1.55%
Ye,Yun-Qing Director 11.39% ACADEMIA SINICA
Chen,Shun-Ling Director 11.39% ACADEMIA SINICA
Ma,Bao-Lin Director 0.00%
Wu,Zong-Yi Director 2.84%
Liu,Xuan-Da Independent Director 0.00%
Qian,Zong-Liang Independent Director 0.00%
He,Hong-Neng Independent Director 0.00%
營業項目
  • Research and Experimental Development on Natural Sciences and Engineering(721000)
  • Retail Sale of Pharmaceutical and Medical Goods in Specialized Stores(475112)
  • 公司歷程
  • Change Person in Charge to Chen,Zhao-Long
    2018/01/15
  • Change Person in Charge to Chen,Zhen-Wen
    2017/10/27
  • Change Person in Charge to Chen,Liang-Bo
    2016/05/19
  • Change Capital to 2,500,000,000
    2014/07/31
  • Change Capital to 1,200,000,000
    2013/05/20
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2024 2023 2022
    Operating income 3,580 0 60
    Operating cost 1,870 0 1
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 1,710 0 59
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 1,710 0 59
    Operating expenses 251,003 268,998 350,959
    Other gain (loss), net - - -
    Operating profit (loss) -249,293 -268,998 -350,900
    Non-operating income and expenses 37,067 -37,089 12,507
    Net profit (loss) before tax -212,226 -306,087 -338,393
    Income tax expense (benefits) - - -
    Net profit (loss) of ongoing business for the current period -212,226 -306,087 -338,393
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -212,226 -306,087 -338,393
    Other comprehensive profit (loss), net 41 43 458
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -212,185 -306,044 -337,935
    Net profit (loss) attributable to owners of parent company -212,226 -306,087 -338,393
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company -212,185 -306,044 -337,935
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 0 -1 -1
    項目 2024 2023 2022
    Net cash inflow (outflow) from operating activities -217,380 -291,126 -249,504
    Net cash inflows (outflows) from investing activities 49,400 -1,859,431 -9,011
    Net cash inflow (outflow) from financing activities -14,039 1,848,644 -13,899
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 41 48 87
    Increase (decrease) in cash and cash equivalents in the current period -181,978 -301,865 -272,327
    Beginning balance of cash and cash equivalents 203,792 505,657 777,984
    Ending balance of cash and cash equivalents 21,814 203,792 505,657
    項目 2024 2023 2022
    Current asset 2,417,393 2,643,014 1,079,450
    Non-current asset 463,892 443,017 522,807
    Total asset 2,881,285 3,086,031 1,602,257
    Current liability 116,186 106,032 168,895
    Non-current liability 16,389 4,800 4,800
    Total liability 132,575 110,832 173,695
    share capital 2,140,105 2,140,105 1,839,935
    Equity - secruity token - - -
    capital reserve 1,129,622 1,688,244 135,733
    retained earning -518,313 -850,405 -544,318
    Other equity -2,704 -2,745 -2,788
    Treasury stock - - -
    Total equity attributable to owners of parent company 2,748,710 2,975,199 1,428,562
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 2,748,710 2,975,199 1,428,562
    Share capital awaiting retirement (unit: share) - - -
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 12 13 7
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額 0
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額 0
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    2024 01-04 0~0.5M 0M
    2023 01-3 0M 0M
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    商標
  • CHO PHARMA
  • CHOptimax
  • 醣基生醫
  • CHO圖樣
  • 專利
  • 抗體藥物複合體
  • 抗體、結合片段及使用方法
  • 抗體藥物複合體
  • 利用醣苷內切酶突變體重塑醣蛋白及其使用方法
  • 利用醣苷內切酶突變體重塑醣蛋白及其使用方法
  • 利用醣苷內切酶突變體重塑醣蛋白及其使用方法
  • 政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
    勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。